Cargando…
The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
BACKGROUND: The FDA issued 2 main drug safety communications (DSCs) on the cardiovascular safety of tiotropium in March 2008 (warning of a potential increased stroke risk) and January 2010 (informing of an absence of a significant increased stroke risk or cardiovascular events based on findings from...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398184/ https://www.ncbi.nlm.nih.gov/pubmed/29952703 http://dx.doi.org/10.18553/jmcp.2018.24.7.700 |
_version_ | 1785084018853675008 |
---|---|
author | Major, Jacqueline M. Zhou, Esther H. Ding, Yulan Ly, Thomas Li, Jie Pinheiro, Simone P. Seymour, Sally |
author_facet | Major, Jacqueline M. Zhou, Esther H. Ding, Yulan Ly, Thomas Li, Jie Pinheiro, Simone P. Seymour, Sally |
author_sort | Major, Jacqueline M. |
collection | PubMed |
description | BACKGROUND: The FDA issued 2 main drug safety communications (DSCs) on the cardiovascular safety of tiotropium in March 2008 (warning of a potential increased stroke risk) and January 2010 (informing of an absence of a significant increased stroke risk or cardiovascular events based on findings from a large trial). OBJECTIVE: To describe the effect of the FDA DSCs on medication dispensing of tiotropium in a large U.S. claims database. METHODS: Initiation of tiotropium products among patients with chronic obstructive pulmonary disease (COPD) aged 40 years and older was determined monthly from 2006-2012 using medication dispensing from the IMS Lifelink Health Plan Claims Database. Similarly, monthly initiation of products containing long-acting beta-agonists (LABAs) was calculated to explore product switching. The effect of the 2008 and 2010 FDA DSCs was measured using interrupted time-series analysis. Subgroups of patients with greater cardiovascular risk were also examined. RESULTS: A decreasing trend in initiation of tiotropium-containing products was present before the initial 2008 DSC. The decline in tiotropium initiation continued until January 2010, accompanied by an increased initiation of LABA-containing products in patients with COPD. In the presence of the existing decreasing trend, the initial DSC was followed by an immediate 2.8% (P = 0.02) further reduction in tiotropium initiation. Tiotropium initiation increased 2.5% (P = 0.03) immediately after the 2010 DSC, reducing the overall decline in rate and stabilizing (flattening) the trend. No significant changes in dispensing level or trend were observed among COPD patients with cardiovascular comorbidity. CONCLUSIONS: Cardiovascular safety concerns may have affected tiotropium initiation as indicated by the decrease in tiotropium dispensing shown immediately following the initial DSC. The effect was alleviated as concerns lessened following the most recent DSC. |
format | Online Article Text |
id | pubmed-10398184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103981842023-08-04 The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study Major, Jacqueline M. Zhou, Esther H. Ding, Yulan Ly, Thomas Li, Jie Pinheiro, Simone P. Seymour, Sally J Manag Care Spec Pharm Research BACKGROUND: The FDA issued 2 main drug safety communications (DSCs) on the cardiovascular safety of tiotropium in March 2008 (warning of a potential increased stroke risk) and January 2010 (informing of an absence of a significant increased stroke risk or cardiovascular events based on findings from a large trial). OBJECTIVE: To describe the effect of the FDA DSCs on medication dispensing of tiotropium in a large U.S. claims database. METHODS: Initiation of tiotropium products among patients with chronic obstructive pulmonary disease (COPD) aged 40 years and older was determined monthly from 2006-2012 using medication dispensing from the IMS Lifelink Health Plan Claims Database. Similarly, monthly initiation of products containing long-acting beta-agonists (LABAs) was calculated to explore product switching. The effect of the 2008 and 2010 FDA DSCs was measured using interrupted time-series analysis. Subgroups of patients with greater cardiovascular risk were also examined. RESULTS: A decreasing trend in initiation of tiotropium-containing products was present before the initial 2008 DSC. The decline in tiotropium initiation continued until January 2010, accompanied by an increased initiation of LABA-containing products in patients with COPD. In the presence of the existing decreasing trend, the initial DSC was followed by an immediate 2.8% (P = 0.02) further reduction in tiotropium initiation. Tiotropium initiation increased 2.5% (P = 0.03) immediately after the 2010 DSC, reducing the overall decline in rate and stabilizing (flattening) the trend. No significant changes in dispensing level or trend were observed among COPD patients with cardiovascular comorbidity. CONCLUSIONS: Cardiovascular safety concerns may have affected tiotropium initiation as indicated by the decrease in tiotropium dispensing shown immediately following the initial DSC. The effect was alleviated as concerns lessened following the most recent DSC. Academy of Managed Care Pharmacy 2018-07 /pmc/articles/PMC10398184/ /pubmed/29952703 http://dx.doi.org/10.18553/jmcp.2018.24.7.700 Text en Copyright © 2018, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Major, Jacqueline M. Zhou, Esther H. Ding, Yulan Ly, Thomas Li, Jie Pinheiro, Simone P. Seymour, Sally The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study |
title | The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study |
title_full | The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study |
title_fullStr | The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study |
title_full_unstemmed | The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study |
title_short | The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study |
title_sort | effect of fda drug safety communications on patterns of tiotropium dispensing: a u.s. health plan claims database study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398184/ https://www.ncbi.nlm.nih.gov/pubmed/29952703 http://dx.doi.org/10.18553/jmcp.2018.24.7.700 |
work_keys_str_mv | AT majorjacquelinem theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT zhouestherh theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT dingyulan theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT lythomas theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT lijie theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT pinheirosimonep theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT seymoursally theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT majorjacquelinem effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT zhouestherh effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT dingyulan effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT lythomas effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT lijie effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT pinheirosimonep effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy AT seymoursally effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy |